 DALLAS, Sept. 09, 2022 GLOBE NEWSWIRE -- Instil Bio, Inc. Instil Nasdaq: TIL, a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference: 